Clinical usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography and carbohydrate antigen 19-9 in patients with periampullary tumors

Abstract

Purpose The prognosis of periampullary cancer varies with its origin and early diagnosis influences outcome. Endoscopic ultrasound, computed tomography, fine needle aspiration, and fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT) are helpful for diagnosis. This study evaluates the diagnostic efficacy of 18FDG-PET for preoperative periampullary tumors. Methods A series of 100 patients undergoing 18FDG-PET/CT before surgical resection of periampullary tumors between March 2011 and February 2019 were enrolled. Maximum standardized uptake value (SUVmax) and carbohydrate antigen 19-9 (CA19-9) levels were compared with pathohistological confirmation of periampullary tumors. Results The SUVmax and uptake range varied with the origin of the periampullary tumors. The SUVmax was not available for 17 of the 42 pancreas tumors, three of 30 common bile duct tumors, and four of 18 ampulla of Vater tumors. The median SUVmax was 0.0 in benign tumors and 5.05 in malignant tumors. The mean SUVmax was 4.1±5.6 in pancreatic tumors, 3.9±2.4 in ampulla of Vater, and 6.0±3.7 in common bile duct. The SUVmax was higher in common bile duct tumors than others. CA19-9 level was of diagnostic value in pancreatic tumor patients. The median CA19-9 levels were 7.64 U/mL (range, 2.71–45.05 U/mL) in benign tumors and 91.97 U/mL (range, 26.91–276.60 U/mL) in cancers patients. Conclusion Preoperative SUVmax and CA19-9 level were of diagnostic value for periampullary tumors originating in the pancreas.

Keywords

• pancreas neoplasm
• positron emission tomography computed tomography
• fluorodeoxyglucose f18
• ca-19-9 antigen